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ABSTRACT
Purpose: Diabetic retinopathy (DR) is characterized by an early stage of inflammation and vessel leakage,
and an advanced vasoproliferative stage. Also, neurodegeneration might play an important role in
disease pathogenesis. The aim of this study was to investigate the effect of the Rho kinase (ROCK)
inhibitor, AMA0428, on these processes.
Methods: The response to ROCK inhibition by AMA0428 (1 µg) was studied in vivo using the murine
model for streptozotocin (STZ)-induced diabetes, focusing on early non-proliferative DR features and the
oxygen-induced retinopathy (OIR) model to investigate proliferative DR. Intravitreal (IVT) administration
of AMA0428 was compared with murine anti-VEGF-R2 antibody (DC101, 6.2 µg) and placebo (H2O/PEG;
1C8). Outcome was assessed by analyzing leukostasis using fluorescein isothiocyanate coupled con-
canavalin A (FITC-ConA) and vessel leakage (bovine serum albumin conjugated with fluorescein iso-
thiocyanate; FITC-BSA)/neovascularization and neurodegeneration by immunohistological approaches
(hematoxylin and eosin (H&E), terminal deoxynucleotidyl transferase–mediated biotinylated UTP nick
end labeling (TUNEL), Brn3a). ELISA and Western blotting were employed to unravel the consequences
of ROCK inhibition (1 µM AMA0428) on myosin phosphatase target protein (MYPT)-1 phosphorylation,
endothelial nitric oxide synthase (eNOS) phosphorylation, and vascular endothelial growth factor (VEGF)
levels in retinas of diabetic mice, on NF-κβ activity and ICAM-1 expression in endothelial cells (ECs).
Results: In vivo, AMA0428 significantly reduced vessel leakage and neovascularization, respectively, in the STZ
andOIRmodel, comparable to DC101 therapy. Additionally, the ROCK inhibitor decreased neurodegeneration
in both models and inhibited leukostasis by 30% (p < 0.05) in the STZ model (p < 0.05), while DC101 had no
positive effect on the outcome of these latter processes. ROCK activity was upregulated in the diabetic retina
and AMA0428 administration resulted in decreased phospho-MYPT-1, enhanced phospho-eNOS, and reduced
VEGF levels. In vitro, AMA0428 interfered with NF-κβ activity, thereby inhibiting ICAM-1 expression in ECs.
Conclusions: Targeting ROCK with AMA0428 effectively attenuated outcome in an early DR model (STZ)
and a late vasoproliferative retinopathy model (OIR). These findings make AMA0428 a promising
candidate with an additional anti-inflammatory and neuroprotective benefit for DR patients, as com-
pared with anti-VEGF treatment.
ARTICLE HISTORY
Received 13 July 2015
Revised 7 March 2016
Accepted 19 April 2016
KEYWORDS
Anti-vascular endothelial
growth factor; diabetic
retinopathy; oxygen-induced
retinopathy model; rho
kinase inhibition;
streptozotocin-induced
retinopathy model
Introduction
In developed countries, diabetic retinopathy (DR) is a major
cause of visual impairment in the working-age population.1
Due to the Western lifestyle, the number of diabetes mellitus
(DM) patients expands, thereby also increasing the occurrence
of DR, a frequent microvascular complication of diabetes.
Loss of vision in DR is due to changes in retinal architecture
caused by abnormal angiogenesis in response to inflammation and
tissue ischemia. Inflammation, a major component of diabetes,
contributes to leukostasis and breakdown of the blood–retinal
barrier (BRB).2,3 As a result of the diabetic microvasculopathy,
hypoxia increases, which itself induces neovascularization. The
newly formed anomalous blood vessels cause leakage, edema,
and even tractional retinal detachment, amajor vision-threatening
complication in proliferative retinopathies. Besides inflammation
and neovascularization, also retinal degeneration is a feature of
DR.4,5 Indeed, DR has several characteristics of a chronic neuro-
degenerative retinal disease, including changes in electrophysiolo-
gical activity, neural apoptosis, and glial reactivity.4,5 This
disruption of neuronal outputmight explain why, despite effective
treatment of the vascular injury, many patients still suffer from
vision impairment. Moreover, findings suggest that the neurode-
generative process might start even before the development of
microvasculopathy.6 As such, it is obvious that the neurodegen-
erative process forms a critical aspect of vision loss in several
retinopathies and is an important target for therapeutic
intervention.
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The approved therapeutic options for proliferative retinopa-
thies consist of destroying part of the retina by laser, in order to
diminish hypoxic tissue7 and/or anti-VEGF (vascular endothe-
lial growth factor) therapy to prevent blood vessels from grow-
ing back.8 Anti-VEGF injections are the first line treatment for
macular edema in DR,8 despite the fact that it potentially
carries the risk of capillary drop-out due to pericyte regression,
thereby exacerbating the ischemic process.9 Furthermore, inhi-
bition of VEGF only seems effective to a certain level, as it is
mostly anti-angiogenesis driven, with only limited impact on
inflammatory processes.10,11 Another concern is that anti-
VEGF treatment generates not only local but also systemic
side effects due to regression of blood vessels and
neurodegeneration.12–16 Besides anti-VEGF, corticosteroids
are being applied in DR, but they may cause cataract and/or
glaucoma.17,18 Hence, there is still a pertinent need for new
treatment strategies to address the unyielding pathology of DR.
An innovative approach, targeting not only angiogenesis but
also inflammation and even neurodegeneration, will be neces-
sary for an improved outcome in visual acuity in proliferative
retinopathy patients. An attractive target for candidate drugs is
rho kinase (ROCK). The rho family of small GTPases controls a
diverse array of cellular processes, including a number of angio-
genic processes, but also inflammation.19–24 Indeed, ROCK is
induced by a variety of vasoactive agents, such as VEGF, result-
ing in endothelial hyperpermeability.25 Activated RhoA/ROCK
also mediates inflammation by unleashing the RelA/p65 subunit
of NF-κβ, so it can migrate to the nucleus and activate transcrip-
tion of target genes including intercellular adhesion molecule-1
(ICAM-1) and several interleukins in vascular endothelial cells
(ECs).26–29 This increased endothelial expression of ICAM-130,31
is known to significantly increase the adherence of leukocytes to
the vascular wall of retinal blood vessels in DR patients.32
Notably, ROCK inhibition by fasudil was previously shown to
ameliorate diabetes-induced microvascular damage by mediat-
ing an increased endothelial nitric oxide synthase (eNOS) phos-
phorylation, a reduced phosphorylation of myosin phosphatase
target protein (MYPT)-1 and decreased ICAM-1 expression.22
Furthermore, recent studies revealed that ROCK signaling is also
associated with the pathogenesis of neurodegeneration33,34 and
suggest that ROCK inhibition could protect against neuronal
damage. Indeed, ROCK inhibitors were recently reported to
protect the retina against excitotoxicity,33,34 as well as to aug-
ment neurite outgrowth.35–38 Overall, these findings indicate the
neuroprotective capacity of ROCK inhibition.
In this study, a potent and novel ROCK inhibitor, AMA0428
(Amakem Therapeutics, Diepenbeek, Belgium),39,40 was inves-
tigated to gain insights into the potential therapeutic effect of
ROCK inhibition on inflammatory, neoangiogenic, and neuro-
degenerative processes underlying DR. Overall, our data show
that ROCK inhibition could be an alternative therapy for anti-
VEGF in the treatment of this blinding retinopathy.
Materials and methods
Animals
Male C57BL/6J mice were obtained from Charles River
Laboratories (L’Arbresle, Cedex, France) and Swiss foster
mothers were acquired from the KU Leuven animal facility.
Housing and all experimental animal procedures were
approved by the Institutional Animal Care and Research
Advisory Committee of the KU Leuven, according to the
2010/63/EU Directive. All animal procedures were performed
in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research, using the guide-
lines of our own institution.
Compounds
In this study, the ROCK inhibitor AMA0428 (1 µg) was tested
in comparison with vehicle H2O-polyethylene glycol (PEG 400;
Fagron NV, Waregem, Belgium) (both provided by Amakem
Therapeutics). A positive control group was treated with the
well-characterized rat anti-mouse VEGF-R2 antibody,
DC10141,42 (6.2 µg), and compared with administration of an
isotype-matched control antibody (1C8; 4.8 µg; both provided
by ThromboGenics NV, Heverlee, Belgium). In all experiments,
the treatment groups constituted out of 10 mice and only 1 eye
per mouse was used to avoid any contralateral effects.
Intravitreal (IVT) injections (1 µl) in the different models
were performed using an analytic science syringe (SGE
Analytic Science, Victoria, Australia) and glass capillaries as
previously described.43,44
Streptozotocin-induced diabetic model
To investigate the in vivo potential of AMA0428 for the
treatment of early non-proliferative DR, the streptozotocin
(STZ)-induced murine model for DR was used.45 C57BL/6J
mice (3–5 weeks old) were rendered diabetic with five con-
secutive daily intraperitoneal (IP) injections of STZ (Sigma
Aldrich, St. Louis, MO, USA) at 55 mg/kg, freshly dissolved in
citrate buffer (pH 4.5). Development of diabetes was defined
by blood glucose levels higher than 250 mg/dl and was mon-
itored weekly after the first STZ injection (glucometer:
OneTouch Vita; LifeScan, Inc., Milpitas, CA, USA). Only
animals with consistently elevated glucose levels were consid-
ered diabetic. No exogenous insulin treatment was given.
Seven weeks after DM onset, mice were anesthetized with
an IP injection of 60 mg/kg sodium pentobarbital
(Nembutal™, CEVA, Sante Animale, Brussels, Belgium) and
received an IVT injection of AMA0428 or vehicle in one eye.
As a positive and negative control, another group was treated
with DC101 or 1C8. Animals were sacrificed 3 days (to
investigate leukostasis) or 1 week (to evaluate vessel leakage)
after initiation of treatment. To check the neuroprotective
properties of AMA0428, mice received an IVT injection
every 2 weeks, starting from week 2 after DM onset until
week 10 and were sacrificed at week 12 by cervical dislocation.
Time points for treatment and sacrifice, depicted in
Figure 1A, were based on the onset of DR in previously
performed studies.5,45–48
Oxygen-induced retinopathy model
The murine oxygen-induced retinopathy (OIR) model49 was
used to investigate the effect of ROCK inhibition on the late
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stages of vasoproliferative retinopathy. Litters of 7-day-old
pups (C57BL/6J) with two nursing dams (Swiss) were sub-
jected to hyperoxia (75% oxygen) in a neonatal incubator
(Inkubator-Aggregat 7011, Dräger, Wemmel, Belgium) from
postnatal day (P)7 to P12. The incubator was connected to a
central hospital oxygen line, allowing adjustment of oxygen
concentration to 75 ± 2%. Oxygen concentration was mon-
itored with a MSA oxygen analyzer (MiniOX 3000, OH,
USA). The cage temperature was 28 ± 2°C with an air humid-
ity of 50%. Food and water were provided ad libitum, but the
chamber was not opened during the hyperoxia period. At P12,
the animals were returned to room air (21% oxygen), which is
known to cause neovascularization of the retina due to a
relative hypoxia.
At P12, mice were anesthetized via an IP injection of
NembutalTM and received an IVT injection of AMA0428 or
vehicle. As a positive control, another group of pups was
treated with the rat anti-mouse VEGF-R2 antibody,
DC101,41,42 or its control antibody 1C8. Each litter was
divided over the four different treatment groups, so that all
treatment groups consisted of different litters, thereby cir-
cumventing a possible variable response between litters in
the disease model.50 Mice were sacrificed at P13 or P17 by
cervical dislocation. Time points for treatment and sacrifice,
all depicted in Figure 1B, were based on previously performed
studies.44,49,51
Leukostasis assay
To analyze the effect of AMA0428 on adherent retinal leuko-
cytes in the STZ model, a perfusion labeling technique was
used, as previously reported,52 with slight modifications. The
retinal vasculature and adherent leukocytes were imaged with
fluorescein isothiocyanate coupled concanavalin A (FITC-
ConA; FL-1001, Vector Laboratories, Inc., Burlingame, CA,
USA). In short, animals were deeply anesthetized with
Nembutal. The chest cavity was carefully opened, and a per-
fusion cannula (21 gauge) was introduced into the aorta. After
drainage was achieved from the right atrium, the animals were
perfused for 2 min with PBS to remove erythrocytes and non-
adherent leukocytes. Perfusion with FITC-ConA (40 µg/ml in
PBS; 5 mg/kg BW) was then performed to label adherent
leukocytes and vascular ECs, followed by removal of residual
unbound lectin with PBS perfusion for 2 min. The eyes were
fixed in 1% paraformaldehyde (PFA) overnight. The next day,
the retinas were carefully removed, and flat mounted on a
slide containing a drop of Vectashield mounting medium
(Vector Laboratories) to prevent the fluorescent dye from
bleaching. The total number of adherent leukocytes in the
retinal arterioles, venules, and capillaries was determined,
according to Joussen et al.52 Retinae in which the peripheral
collecting vessels of the ora serrata were not visible were
discarded.
Vessel leakage assay
Vessel leakage was assessed in the STZ model at week 8 post
DM onset with an approach adapted from previous studies on
mice.53,54 Bovine serum albumin conjugated with fluorescein
isothiocyanate (FITC-BSA, 100 µg/g, Sigma Aldrich) was
injected intravenously. Thirty minutes later, the mice were
sacrificed by cervical dislocation, eyes were enucleated and
Figure 1. Experimental setup of the streptozotocin (STZ) and oxygen-induced retinopathy (OIR) models depicted in summarizing schemes with treatment and
sacrifice time points. (A) The left panel shows a diagram of the STZ experiments in which C57BL/6J mice are rendered diabetic with five consecutive daily
intraperitoneal (IP) injections. Diabetes mellitus (DM) onset was typically seen at week (W) 1 or 2 post STZ injection. (B) The right panel shows a diagram of the OIR
experiments in which C57BL/6J pups with a Swiss foster mother are subjected to hyperoxia (75% oxygen) from postnatal day (P) 7 to P12, which obliterates
capillaries in the retina. On P12, the animals are returned to room air, which then results in the formation of neovascular tufts, which are known to be maximal at
P17, the time of sacrifice. Regression of neovascularization and normalization of the vascular pattern, which is known to occur after P17, was not studied here. FITC-
ConA, fluorescein isothiocyanate coupled concanavalin A; FITC-BSA, bovine serum albumin conjugated with fluorescein isothiocyanate; H&E, hematoxylin and eosin;
RGCs, retinal ganglion cells; IHC, immunohistochemical; TUNEL, terminal deoxynucleotidyl transferase–mediated biotinylated UTP nick end labeling.
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placed in 4% PFA overnight followed by paraffin wax embed-
ding. Sagittal serial sections (7 µm) through the central retina
were collected on five microscopy slides (35 µm between
consecutive sections on one slide). Sections of one glass slide
were dewaxed and vessel leakage was assessed with a fluores-
cence microscope on six cross-sections in total: three sections
on either side of the optic nerve head (spaced 70 µm). So,
cross-sections that included the optic nerve were excluded.
Fluorescent intensities were measured on 12 nonvascular ret-
inal images, including all retinal layers, collected in the central
part of the retina (2 images of each section). The retinal
fluorescent intensity per image was then normalized to the
background fluorescent intensity on the slide.
(Immuno)histochemistry and histological analysis
Neovascularization
To evaluate the pattern of retinal neovascularization in the
OIR mouse model, mice were sacrificed at P17 and eyes
were dissected and fixed overnight in 1% PFA. Before per-
forming a hematoxylin and eosin (H&E) staining, the eyes
were dehydrated (Shandon Exelsior ES; Thermo Fisher
Scientific, Rochester, NY, USA), embedded in paraffin, and
sagittal sections (7 µm) were positioned in series on five
microscopy slides (35 µm between consecutive sections on
one slide). Neovascularization was investigated according to
Smith et al.44,49 In short, the total number of vascular nuclei,
extending from the internal limiting membrane into the
vitreous, was counted per retinal cross-section, on four sec-
tions on each side of the optic nerve head (eight sections per
eye, spaced 35 µm). These vascular cell nuclei, identified
under light microscopy, were considered to be associated
with new vessels if they were found on the vitreal side of
the internal limiting membrane. Sections that included the
optic nerve head were excluded.
Neurodegeneration
The process of neurodegeneration in the STZ and the OIR
model was evaluated by different (immuno)histological stain-
ings. First, a H&E staining was performed on one series of
sections to localize the optic nerve head and measure retinal
layer thickness and retinal ganglion cell (RGC) density at week
12 post DM onset in the STZ model and P17 in the OIR model.
Next, within the STZ model, viable RGCs were visualized
by Brn3a immunostaining at week 12 post DM onset. The
serial sections were incubated overnight with goat anti-Brn3a
antibody (1/750; SC31984; SantaCruz Biotechnology, Inc.,
Heidelberg, Germany). The next day, the slides were washed
and incubated for 2 h with rabbit anti-goat (RAG)-Alexa-488
(1/200; A11078; Molecular Probes, Eugene, OR, USA).
Afterward, slides were mounted with Prolong Gold with
DAPI (Molecular Probes). Retinal layer thickness and RGC
density were measured in the central retina at two locations,
one on either side of the optic nerve. In short, digitalized
images of three different serial sections (70 µm apart) contain-
ing the optic nerve head were used (six measurements in
total). To quantify RGC density, ganglion cell nuclei were
counted 300 µm from the optic nerve head on a defined
length of the retina (250 µm on either side of the optic
nerve head). These six data points were averaged for each
eye and the mean values from the individual eyes were statis-
tically analyzed. This was done both on the H&E stained and
Brn3a immunostained serial sections. Alternatively, within the
OIR model, terminal deoxynucleotidyl transferase–mediated
biotinylated UTP nick end labeling (TUNEL) was used to
detect apoptotic retinal cells at P13, a time point previously
shown to be characterized by retinal cell death.51 In short,
serial sections were deparaffinized, rinsed, and treated with
proteinase K (1/500; Qiagen, Venlo, The Netherlands) for 15
min. Next, sections were incubated with the TUNEL reaction
mixture (In Situ Cell Death Detection Kit, POD; Roche,
Mannheim, Germany) at 37°C for 1 h. Afterward, the slides
were mounted with Prolong Gold containing DAPI
(Molecular Probes). To characterize the cell loss observed in
the retina of OIR mice, six sagittal sections containing the
optic nerve head were scanned systematically from the tem-
poral to the nasal ora serrata for fluorescent cells indicative of
apoptosis. Positive labeled cells were counted at six serial
sections/eye and averaged as number of TUNEL positive
cells/section.
Cells and culture conditions
Human umbilical vein endothelial cells (HUVEC, Lonza,
Walkersville, MD, USA) were cultured in 0.1% gelatin
(Invitrogen, Carlsbad, CA, USA) coated T75 flasks (Sciencell
Research Laboratories, Carlsbad, CA, USA). Cells were main-
tained in complete EGM-2 medium, supplemented with 5%
fetal bovine serum (FBS, Thermo Fisher Scientific), 0.1%
human recombinant epidermal growth factor, 0.4% recombi-
nant human fibroblast growth factor, 0.1% VEGF, 0.1%
recombinant lung insulin-like growth factor, 0.04%
Hydrocortisone, 0.1% ascorbic acid, 0.1% heparin, and 0.1%
gentamicin sulfate amphotericin-B (EBM-2 bullet kit; Lonza).
The cells were routinely maintained at 37°C in a humidi-
fied atmosphere of 5% CO2 and medium was replaced every
2–3 days. Cells between third and sixth passage were used in
all experiments. All in vitro assays were repeated at least three
times in triplicate.
ELISA
ROCK activity and VEGF expression levels
To evaluate expression and activity of ROCK in the STZ model,
retinas were isolated from non-diabetic control mice and from
STZ-injected mice at 2, 5, 7, and 8 weeks after DM onset. To
unravel the efficacy of AMA0428 for inhibiting ROCK activity
and to investigate the effect of ROCK inhibition on VEGF
levels, a second group of mice received an IVT injection of
vehicle or AMA0428 at 7 weeks post DM onset, and retinas
were dissected 3 days or 1 week later. Cell lysates from retinal
samples, containing both retinas of one mouse, were obtained
using the Mammalian Cell Lysis kit (Sigma-Aldrich). ROCK
and VEGF levels were determined via ELISA using the ROCK
Activity Assay (CSA001, Millipore, Billerica, MA, USA) and the
Quantikine ELISA kit for mouse VEGF (R&D Systems,
Minneapolis, MN, USA), respectively. Absorbance values were
obtained with the MultiskanTM FC Microplate Photometer
4 K. HOLLANDERS ET AL.
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(Thermo Scientific, Waltham, MA, USA) and statistically ana-
lyzed using one-way ANOVA.
NF-κβ activity
To investigate the effect of AMA0428 on the NF-κβ pathway in
HUVECs, an ELISA (Human/Mouse/Rat Phopho-RelA/NF-κβ
p65 (S536) immunoassay; R&D Systems) was used to measure
phosphorylated RelA/NF-κβ p65. In short, HUVECs were pla-
ted in a 96-well plate at a density of 10–20 × 103 cells per well
until they reached semi-confluence. Before treatment, cells
were washed with PBS and incubated in serum-free medium
for 0.5–1 h prior to incubation with AMA0428 (1 µM) with or
without thrombin (5 units/ml; Enzyme laboratories, South
Bend, IN, USA; stimulation of HUVEC). Six hours after drug
exposure, cells were fixed with 4% PFA. According to the
manufacturer’s instructions, primary and secondary antibody
mixtures were added to each well. Finally, the fluorogenic
substrates were added and fluorescence was measured
(Fluorskan Ascent FL, Thermolabsystems, Helsinki, Finland)
and calculated as phosphorylated RelA/NF-κβ p65 over total
RelA/NF-κβ p65 in the cells.
Western blotting
Phospho-eNOS
The same retinal samples from STZ vehicle- and AMA0428-
treated mice, used within the ROCK and VEGF ELISA, were
also applied in Western blotting for detection of phospho-
eNOS. Equal amounts of retinal homogenates were loaded
onto 4%–12% Bis-Tris polyacrylamide gels (BioRad
Laboratories, Hercules, CA, USA) and transferred to nitrocellu-
lose membranes. Following 2 h incubation with 5% BSA and
0.1% Tween in 1× Tris-buffered saline to avoid non-specific
binding, the membrane was incubated overnight at 4°C with
the rabbit polyclonal antibody anti-Phospho-eNOS (1:200, 9571,
Cell Signaling, Danvers, MA, USA). After 45 min of incubation
with horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (1:20,000, DakoCytomation A/S, Copenhagen, Denmark),
protein bands were visualized using the luminol-based enhanced
chemiluminescent kit (SuperSignal West Dura, Thermo
Scientific, Waltham, MA, USA) on the ChemiDoc MP
Imaging System (BioRad Laboratories, Hercules, CA, USA).
Optical density analyses were performed for the specific bands,
as well as for LavaPurple (Gelcompany, San Francisco, CA,
USA) total protein stain, using Image Lab 4.1 software
(BioRad Laboratories, Hercules, CA, USA).
ICAM-1
Cell lysates of HUVECs at 80%–90% cell confluence were
obtained. All protein concentrations were measured using
the Pierce BCA Protein Assay kit (Thermo Scientific,
Rochester, NY, USA). Equal amounts of protein from each
sample were separated by electrophoresis using Mini-
PROTEAN® TGXTM Precast gels (BioRad, Temse, Belgium).
Samples of non-treated and treated (1 µM of AMA0428 with
or without 5 units/ml thrombin) cell were run simultaneously
on the same gel. The Trans-Blot® TurboTM Mini
Nitrocellulose Transfer Packs (BioRad) were used to transfer
the separated proteins by electrophoresis. Afterward, the
proteins were blocked with 5% blocking solution (milk pow-
der) and 0.1% Tween-20 (Merck, Overijse, Belgium) in 1×
PBS for 1 h at room temperature (RT). Blots were subse-
quently incubated overnight at 4°C with primary rabbit poly-
clonal antibodies against ICAM-1 (1:200; SantaCruz
Biotechnology, Inc.). The next day, the blots were rinsed
and incubated for 120 min with a secondary antibody
(1:5000) (HRP-conjugated pig anti-rabbit immunoglobulin,
DakoCytomation A/S). Immunoreactivity was visualized
using the Pierce ECL Western Blotting Substrate (Thermo
Scientific). Membranes were incubated with glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; 1:1000; Cell Signaling)
to confirm equal protein loading. Densitometric quantifica-
tion of Western blot signal intensity was performed using the
molecular imager ChemiDocTM XRS combined with
ImageLabTM Software 5.1 (BioRad) and calculated as a per-
centage of the mean value from non-stimulated cells.
Microscopy
Vessel leakage, neovascularization, and neurodegeneration were
analyzed, using a Leica microscope, equipped with a digital
camera (Axiocam MrC5; Zeiss, Oberkochen, Germany), at a
magnification of 20× and a resolution of 2584 × 1936 pixels. As
previously described,44,55 morphometric analyses were per-
formed using commercial software (KS300; Zeiss).
The leukostasis assay was visualized using confocal imaging
Laser ScanningMicroscope (LSM, Olympus, Melville, NY, USA).
LSM-imaging software FluoView (FV10-ASW, Olympus) was
used for digital acquisition and processing of the images.
Statistical analysis
All morphometric data were analyzed using the two-sided
unpaired Student’s t-test for independent samples, unless
otherwise mentioned. p ≤ 0.05 was considered to be statisti-
cally significant. Data are represented as mean ± SEM, unless
otherwise stated. All experiments were analyzed blindly.
Results
AMA0428 inhibited leukostasis, vessel leakage, and
neurodegeneration in the STZ model
First, we investigated the effect of AMA0428 on early non-
proliferative DR features such as leukostasis and vascular perme-
ability, within the STZ mouse model (Figure 1A). Increased
leukocyte counts and ICAM-1 expression have been documen-
ted in the human retinal vasculature of eyes with DR.32 Based on
previous reports,46,47 we checked the number of labeled-adher-
ent leukocytes in the mouse STZ model at 7 weeks and 3 days
post DM onset using FITC-ConA perfusion. STZ-induced dia-
betes significantly increased leukostasis in retinal vessels of dia-
betic, non-treated mice, as compared with non-diabetic mice. A
single IVT injection with AMA0428 (1 µg) at week 7 post DM
onset decreased diabetes-enhanced leukostasis, when checked 3
days later, as shown by a significant reduction in the number of
adherent leukocytes/retina by 30.4 ± 6.1%, in comparison with
vehicle-treated animals (p < 0.001; Figure 2A,B). A single
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administration of DC101 (6.2 µg) did not alter leukocyte adhe-
sion in the STZ model at 3 days after single IVT injection and
was found to yield similar results as the control antibody 1C8
treatment (data not shown).
Next, the effect of ROCK inhibition on blood vessel
integrity, another important early process that occurs during
STZ-induced experimental DR pathogenesis, was evaluated.
Breakdown of the BRB characterizes early stages of vascular
dysfunction in both human and experimental diabetes.56,57
Within the mouse STZ model, retinal vessel leakage is
known to manifest around 8 weeks after DM onset.47,53
Retinal vascular permeability, measured by analyzing extra-
vasation of FITC-BSA, showed that a single IVT injection of
AMA0428 (1 µg) at 7 weeks post DM onset decreased vessel
leakage by 27.4 ± 2.0%, compared with vehicle-treated mice
(p < 0.05; Figure 2C). Similarly, DC101 (6.2 µg) administra-
tion inhibited vessel leakage with 32.9 ± 2.2% as compared
with its control antibody 1C8 (n = 10, p < 0.05).
As it has also been reported that STZ-induced diabetes
results in RGC degeneration,5,48 and combined with the
knowledge that the neurodegenerative process might take
place early in disease progress,6 we additionally investigated
the effect of ROCK inhibition on RGC density using H&E
stained retinal sections of mice at 12 weeks after DM onset.
As previously reported,5,48 we also observed that the number
of cells in the RGC layer of vehicle-treated eyes and naive/
non-treated diabetic eyes was similarly reduced by, respec-
tively, 23.3 ± 2.3% and 24.9 ± 2.4%, as compared with non-
diabetic mice. Notably, morphometric analysis revealed a
reduced RGC loss (15.3 ± 1.8%) in mice treated every 2
weeks (week 2–4–6–8–10 after DM onset) with injections
of AMA0428 (1 µg), as compared with vehicle (p < 0.05, data
not shown), at 12 weeks after DM onset. These results were
confirmed by Brn3a immunostaining, which showed signifi-
cantly more viable RGCs when animals were treated with
AMA0428 in comparison with vehicle injected diabetic eyes
(10.5 ± 2.0%; p < 0.05, Figure 3). Of note, DC101 and 1C8
treatment had no effect on RGC density in the STZ model
(data not shown).
Overall, AMA0428 treatment attenuated leukostasis and
vessel leakage, processes characterizing early non-proliferative
DR. Moreover, prolonged administration of the ROCK inhi-
bitor also improved RGC survival in the STZ model.
AMA0428 decreased neovascularization and
neurodegeneration in the OIR model
Within the STZ model, it takes months before actual neovas-
cularization occurs.58,59 Therefore, the therapeutic potential of
the ROCK inhibitor AMA0428 on neo-angiogenic processes
was investigated using the OIR model (Figure 1B), a well-
characterized experimental model for vasoproliferative DR.49,60
Morphometric analysis on H&E serial sections disclosed
that a single IVT injection of AMA0428 (1 µg) at P13, 1 day
upon return of the pups into normoxic conditions, significantly
reduced the number of neovascular nuclei at P17, that is, by
24.2 ± 4.5%, as compared with vehicle-treated eyes (p < 0.001;
Figure 4). This inhibitory effect of AMA0428 on angiogenesis
was similar to the reduction in neoangiogenic response
induced by DC101 (6.2 µg) administration, that is, 17 ± 4.4%
in comparison with its control antibody 1C8.
Besides neoangiogenesis, also neurodegeneration has been
described as an important feature in the OIR model.51,61
Indeed, also in our experiments the retinal thickness of the
central inner nuclear layer (INL) and inner plexiform layer
(IPL) was found to be severely reduced in OIR mice
Figure 2. A single IVT injection of AMA0428 at 7 weeks after DM onset decreases leukocyte adhesion and retinal vessel leakage in the STZ mouse model. (A) Seven weeks
and 3 days after DM onset, leukostasis was significantly increased in the STZ mouse model compared with non-diabetic mice (p < 0.001). IVT administration of AMA0428
at 7 weeks in diabetic mice decreased leukocyte adhesion with 30.4 ± 6.1% compared with vehicle-treated mice (p < 0.001). (B) Representative FITC-ConA perfused flat
mounts of normal/non-diabetic animals (No DM) and diabetic animals (DM) without (non-treated) or with vehicle or AMA0428 treatment. Arrowheads indicate adherent
leukocytes (bar = 25 µm). (C) Vessel leakage, quantified at 8 weeks after DM onset, was significantly inhibited after AMA0428 administration by 27.4 ± 2.0% compared
with vehicle-treated mice (p < 0.05); which was similar to DC101 therapy (32.9 ± 2.2%). Data are represented as mean ± SEM.
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(respectively, 31 ± 3% and 32 ± 2%; Figure 5A,B), as compared
with H&E-stained retinas of room air–raised mice (p < 0.001) at
P17. Other layers (nerve fiber layer, ganglion cell layer, outer
plexiform layer, outer nuclear layer, photoreceptor layer) did not
significantly alter in thickness or general morphology.
Importantly, single IVT administration of AMA0428 (1 µg) at
P13 resulted in a milder decrease in retinal thickness of 10 ± 4%
for the INL and 25 ± 4% of the IPL, as compared with room air–
raised mice (p < 0.05; Figure 5A,B). Of note, DC101 (6.2 µg) or
1C8 treatment did not affect thinning of INL and IPL (data not
shown).
To further investigate whether the observed retinal thinning
at P17 was caused by apoptotic cell death, a TUNEL assay was
performed at P13, 24 h after return to room air and AMA0428
administration. TUNEL-positive cells were found in the central
INL of untreated and vehicle-injected OIR mice. An IVT injec-
tion of pup eyes with AMA0428, however, significantly reduced
the number of TUNEL-positive cells by 33 ± 6% (p < 0.001,
Figure 5C,D). Of note, the RGCs or displaced amacrine cells in
the RGC layer of the ischemic retinas did not undergo cell
death in our model (data not shown).
Overall, our data in the OIR model indicated that ROCK
inhibition decreased neovascularization and inhibited retinal
apoptotic cell death in the INL.
Downstream targets underlying reduced leukostasis and
vessel leakage/neovascularization after inhibition of
ROCK by AMA0428
AMA0428 inhibited NF-κβ activity and ICAM-1 expression in
ECs in vitro
In a previous report, we already showed that AMA428 admin-
istration reduced the permeability of VEGF-stimulated
HUVECs,62 findings that might explain the diminishing effect
of this ROCK inhibitor on vessel leakage in the STZ model.
Here we wished to further investigate its role in attenuating
leukostasis. Diabetes is known to significantly increase the
adherence of leukocytes to the vascular wall due to vascular
damage and increased expression of ICAM-1 on ECs.32
During vascular injury and as a result of the coagulation
cascade, thrombin is formed leading to intravascular
Figure 3. Reduced RGC loss after administration of AMA0428 in the STZ model. (A) Brn3a immunostaining showed a reduction of 19.3 ± 1.7% of viable RGCs 12 weeks
after DM onset in non-treated mice as compared with non-diabetic mice. Treatment with AMA0428 reduced RGC loss, thereby improving RGC density by 10.5 ± 2.0%
compared with vehicle-treated/non-treated diabetic mice (p < 0.05). Data are represented as mean ± SEM. (B) Representative pictures of the central retina (300 µm from
the optic nerve head), where viable RGCs detected by Brn3a immunostaining were counted over a distance of 250 µm; upper left panel: no diabetes mellitus (DM); upper
right panel: non-treated DM; lower left panel: DM treated with vehicle; lower right panel: DM treated with AMA0428 (bar = 100 µm).
Figure 4. IVT administration of AMA0428 significantly reduces neovessel formation in the OIR model. (A) The number of neovascular nuclei in the OIR model is
diminished by 24.2 ± 4.5% after AMA0428 injections compared with vehicle-treated eyes (p < 0.001), which was similar to the 17 ± 4.4% reduction induced by DC101
in comparison with 1C8. Data are represented as mean ± SEM. (B) Representative pictures of H&E stained serial sections at P17 of all treatment arms in the OIR
experiments. Upper left panel: vehicle; lower left panel: AMA0428; upper right panel: 1C8; lower right panel: DC101. Arrows indicate neovascular tufts (bar = 50 µm).
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coagulation,30,31 but also ICAM-1 expression.27 Because of the
essential role of NF-κβ in mediating thrombin-induced tran-
scription of ICAM-1 in ECs27 and the reported link between
activated ROCK and the release of RelA/p65,63 we investi-
gated whether the ROCK inhibitor AMA0428 could intervene
with thrombin-induced NF-κβ activity in HUVECs.
Therefore, a cell-based ELISA was performed to measure
phosphorylated RelA p65, a member of the NF-κβ family.
Indeed, thrombin challenge of HUVECs resulted in increased
NF-κβ activity, whereas exposing the cells to AMA0428 inhib-
ited thrombin-induced NF-κβ activity (Figure 6A).
Additionally, Western blot analysis confirmed that inhibition
of ROCK by AMA0428 impaired the ability of thrombin to
induce ICAM-1 expression in HUVECs (Figure 6B).
Figure 5. Administration of AMA0428 inhibits neuronal cell death in the OIR model. (A,B) Morphometric analysis on H&E stained sections revealed that the inner
nuclear layer (INL) and inner plexiform layer (IPL) are reduced in thickness by, respectively, 31 ± 3% (A) and 32 ± 2% (B) in OIR mice as compared with room air-
raised mice (p < 0.001). (C) The number of TUNEL-positive cells was significantly reduced by 33 ± 6% when AMA0428 was administered, in comparison with vehicle-/
non-treated eyes (p < 0.001). Data are represented as mean ± SEM. (D) Representative pictures of apoptotic cells in the INL of the central P13 retina detected by
TUNEL staining (green nuclei). The different retinal layers are indicated as follows: ganglion cell layer (GCL), INL, and IPL. Left panel: non-treated; middle panel:
vehicle-treated; right panel: AMA0428-treated eyes (bar = 50 µm).
Figure 6. Exposure of HUVECs to AMA0428 inhibits thrombin-induced NF-κβ activity and ICAM-1 expression. Confluent HUVEC monolayers were challenged with
thrombin (5 units/ml) with/without AMA0428 (1 µM). (A) Using a cell-based ELISA to measure phosphorylated RelA/NF-κβ p65 an impaired ability of thrombin to
induce NF-κβ activity in HUVECs was observed after treatment with AMA0428. Bar graph represents the amount of phosphorylated over the amount of total RelA/NF-
κβ p65 and is expressed as percentage relative fluorescence units (RFUs). Data are represented as mean ± SEM (n = 3). (B) AMA0428 inhibits the effect of thrombin to
induce ICAM-1 expression in HUVECs, as shown on the representative picture (right panel). Total cell lysates were immunoblotted with an anti-ICAM-1 antibody. The
bar graph (left panel) is a representative dataset of ICAM-1 protein expression normalized to GAPDH levels (ICAM-1/GAPDH ratio in arbitrary units).
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Thus, our data showed that AMA0428 intervenes with the
NF-κβ pathway, thereby inhibiting thrombin-induced ICAM-
1 expression in ECs.
AMA0428 suppressed phosphorylation of MYPT-1,
increased phospho-eNOS levels, and reduced VEGF levels in
the diabetic mouse retina in vivo
To confirm the contribution of the ROCK pathway in the
pathology of DR previously observed in the diabetic rat retina,64
an ELISA assay was used to determine ROCK activity levels in
the retinas of mice subjected to the STZ model. This assay is
based on phosphorylation of threonine residue 696 of MYPT-1,
the major regulatory subunit of myosin phosphatase (MP) and
considered a surrogatemarker for ROCK activity.65 ROCK levels
clearly increased in the diabetic mouse retina and reached sig-
nificant upregulated levels at 8 weeks post DM onset, as com-
pared with non-diabetic animals (p < 0.05) (Figure 7A). To
investigate the efficacy of AMA0428, ROCK activity was mea-
sured in vehicle- and AMA0428-treated eyes at the time points
corresponding to elevated ROCK activity in this model, more
specifically, at 3 and 7 days after the IVT injection, performed at
7 weeks post DMonset. This experiment confirmed the observed
increase in ROCK activity, hence MYPT-1 phosphorylation,
between 7 and 8 weeks post DM onset in vehicle-treated retinas
(Figure 7B) and revealed that treatment with AMA0428 signifi-
cantly reduced the enhanced MYPT-1 phosphorylation in dia-
betic retinas (Figure 7B), thereby activating MP. As a
consequence, levels of phosphorylated myosin light chain
(MLC) are supposed to diminish, which might also explain the
observed reduction in leukocyte adhesion.66–69
In addition, we observed significantly increased phos-
phorylated, and thus activated levels of eNOS, another well-
known target of ROCK, in AMA0428-treated eyes as com-
pared with vehicle-treated or non-treated eyes at 7 weeks post
DM onset (Figure 8A). These data are in line with previously
published data, confirming the ability of active ROCK to
(indirectly) dephosphorylate eNOS,70 and thus reduce the
beneficial role of eNOS in DR, which is suggested to prevent
apoptosis and leukocyte adhesion.64,71–73
As VEGF is a well-known inducer of abnormal vessel
growth and vessel leakage in the diabetic retina, and known
to be upregulated within the STZ model,74,75 VEGF levels
were evaluated in vehicle- and AMA0428-treated eyes of
STZ-injected mice. Figure 8B shows a clear upregulation of
VEGF in the vehicle-injected diabetic retina, between 7 and 8
weeks post DM onset. Moreover, application of AMA0428 at
week 7 significantly reduced VEGF levels (p < 0.05) 3 and 7
days later (Figure 8B), which can explain the diminished
vessel leakage after ROCK inhibition in the STZ model.
Discussion
The effect of a novel potent ROCK inhibitor (AMA0428) on
early non-proliferative and advanced vasoproliferative DR was
investigated in two different mouse models. Our results
demonstrate that AMA0428 was effective in improving the
Figure 7. ROCK activity levels are upregulated in the retina of mice subjected to the STZ model and decreased after AMA0428 treatment. (A) ROCK activity, measured
via phosphorylated MYPT-1 levels via ELISA, is clearly elevated in the retina of STZ-treated mice from 2 weeks post DM onset (n ≥ 5). (B) AMA0428 administration at 7
weeks post DM onset significantly reduced ROCK activity levels, measured 3 and 7 days later, as compared with vehicle-treated eyes (n ≥ 4). All data are represented
as mean ± SEM.
Figure 8. Administration of AMA0428 increases phospho-eNOS and reduces VEGF levels. (A) Western blot data on retinal samples, isolated 3 days after AMA0428 or
vehicle administration at week 7 post DM onset, demonstrated clearly elevated phospho-eNOS levels in AMA0428- versus vehicle injected eyes (n ≥ 4).
Representative Western blot images of both conditions are shown. Optic density values were normalized using LavaPurple total protein stain. (B) In STZ-treated
mice, VEGF levels, measured via ELISA, are clearly upregulated in the vehicle-treated retina between 7 weeks/3 days and 8 weeks post DM onset. Single IVT injection
of AMA0428 at weeks 2, 5, and 7 significantly lowers VEGF levels in the diabetic retina (n ≥ 4). All data are represented as mean ± SEM and represented as a
percentage relative to the vehicle-treated condition at 7 weeks/3 days post DM onset.
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outcome of early DR features, like inflammation and vessel
leakage, in the STZ model; as well as improving the late
vasoproliferative stage as demonstrated in the OIR model.
Furthermore, we directly compared the effect of AMA0428
to the well-established VEGF-R2 antibody DC101, and
showed that ROCK inhibition was as effective as DC101 in
reducing vessel leakage and neovascularization, with an addi-
tional inhibitory effect on inflammation and
neurodegeneration.
In addition, our results showed a clear upregulation of
phosphorylated MYPT-1 levels in the retina of STZ-treated
mice. As MYPT-1 is an important downstream mediator of
ROCK, and phosphorylation of MYPT-1 is considered a sur-
rogate marker for ROCK activity,64,66 these findings point
toward enhanced levels of ROCK activity in the diabetic retina
and thus, a role for the Rho/ROCK pathway in DR
pathogenesis.
The present study indicated that ROCK inhibition might
diminish inflammation by reducing leukostasis in the STZ-
induced animal model in vivo, possibly due to inhibiting the
expression of ICAM-1 on ECs as shown in vitro. Indeed, a key
step for stable adhesion of leukocytes to the endothelium
involves expression of ICAM-1 on the endothelial surface,76,77
which is known to be significantly increased in retinal blood
vessels of diabetic patients.32 Activation of NF-κβ and there-
fore expression of ICAM-1 is mediated by thrombin via Rho
GTPase and requires alterations in actin dynamics.27 In
pathological conditions, such as in diabetes, thrombin is
released during intravascular coagulation initiated by vascular
injury.30,31 Thrombin activation of RelA/p65, a subunit of NF-
κβ,78 is mediated by the Rho/ROCK pathway. Indeed, phos-
phorylation by active ROCK is necessary in order for the
RelA/p65 subunit to be released for its nuclear uptake and
activate transcription of target genes including ICAM-1.27–29
Inhibition of ROCK by AMA0428 impaired the ability of
thrombin to induce NF-κβ activity and ICAM-1 expression
in ECs in vitro. These results are in line with previous reports,
which employed the reference ROCK inhibitor Y-27632.27,63
Indeed, the Rho/ROCK pathway, an essential mediator of NF-
κβ, is known to play a critical role in diabetic retinal micro-
vasculopathy, since ROCK inhibition protects the vascular
endothelium by blocking neutrophil adhesion.27,77
Unfortunately, Western blot data could not confirm a
similar reduction in ICAM-1 levels at 3 or 7 days after
AMA0428 administration at 7 weeks post DM onset, as com-
pared with vehicle-treated retinas (data not shown). We sus-
pect that the differences in ICAM-1 expression are too small
to be detected in whole retinal tissue on Western blot, and
that other leukocyte adhesion molecules, such as VCAM-1,
VAP-1, or selectins, or even their binding ligands, integrins,
are also involved in ROCK-mediated leukostasis.79 Indeed, it
has been described that phosphorylation of MLC, downstream
of the Rho/ROCK pathway, is essential for assembly of integ-
rins and controlling the high-affinity state of integrins.71,80,81
Administration of AMA0428 significantly reduced phos-
phorylated MYPT-1 levels in the diabetic retina, thereby
impeding the Rho/ROCK signaling pathway. As a conse-
quence, levels of phosphorylated MLC are supposed to
decrease, which might explain the reduction in leukocyte
adhesion.66–69,82 In addition, significantly increased levels of
phosphorylated and thus activated eNOS were detected in
AMA0428-treated eyes as compared with vehicle-treated
eyes. These data are in line with previously published data,
demonstrating increased levels of phosphorylated eNOS in the
retina of STZ-treated rats after administration of fasudil,
another ROCK inhibitor.64,71 Thus, these and previous results
support the ability of active ROCK to (indirectly) depho-
sphorylate eNOS, and attenuate the beneficial role of eNOS
in DR, for example, preventing leukocyte adhesion.64,70–73,83
Overall, these data point toward the existence of multiple
pathways by which the inhibition of active ROCK can result
in a decreased leukocyte adhesion. The current findings also
complement the previously described anti-inflammatory
results of AMA0428 in the laser-induced CNV mouse
model.84
In the current study, we also demonstrated that the
ROCK inhibitor markedly inhibited early vessel leakage but
also the later stage of neovascularization, similar to what has
been observed after anti-VEGF-R2 administration in, respec-
tively, the STZ and the OIR model. These results confirm the
recently reported anti-angiogenic effect of AMA0428 in the
murine laser-induced CNV model.84 The Rho/ROCK signal-
ing pathway is well-known being activated by several vasoac-
tive agents, such as VEGF, thereby inducing endothelial
hyperpermeability and angiogenesis. Notably, increasing evi-
dence also suggests the existence of a feedback mechanism
by which ROCK influences VEGF levels by interacting with
VEGF-R2.85 Indeed, suppression of the Rho/ROCK pathway
has been demonstrated to inhibit VEGF-induced angiogen-
esis, by mediating EC permeability, proliferation, migration,
as well as pericyte recruitment in vitro.25,84 Moreover, we
previously revealed an inhibition of VEGF upregulation by
AMA0428 in mice subjected to a neovascular AMD model,84
thereby inhibiting vessel leakage/neovascularization.
Similarly, our current results confirm decreased VEGF levels
after AMA0428 treatment in the STZ model and highlight
the interplay between these two molecules in affecting blood
vessel integrity and proliferation. Altogether, our and pre-
vious findings suggest that ROCK inhibition might inhibit
early vessel leakage, as well as the later process of neoangio-
genesis, which is important since both the breakdown of the
existing BRB and the leaky nature of newly formed blood
vessels are known to result in edema, a major cause of severe
visual loss in DR patients.86
Importantly, it has become increasingly clear that not only
the retinal vasculature but also neuronal cells are affected in
DR.4,5 In addition, there is some evidence that neurodegenera-
tion might start even before the development of
microangiopathy.6 Therefore, we investigated this process in
both experimental animal models, representing early and late
changes of retinopathies and started treatment early in disease
onset (week 2 after DM onset in the STZ model/immediately
after return to room air in the OIR model) to have a maximal
effect on the early neurodegenerative processes involved. Rodent
models have been used for years to elucidate the mechanisms of
retinal neuron damage in diabetes. Mohr et al.87 reported
increased levels of caspase activity, a marker for apoptosis, in
retinas of diabetic mice, and Martin et al.48 revealed that cells in
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the RGC layer of the STZ-induced diabetic mouse actually
undergo apoptosis. These findings were also confirmed in the
present study using eyes of untreated or vehicle-treated diabetic
mice. On the contrary, retinas of diabetic mice treated with
AMA0428 showed significantly less apoptotic RGCs. Likewise,
recent studies indicated that besides vascular pathology, neuro-
nal injury is also a feature within the OIR model.88,89 Indeed,
also in our experiments, the INL and IPL were found to be
reduced in thickness, without alterations in the number of
RGCs. These data are in line with earlier reports,51,90 and
suggest that RGCs in newborn mice are better protected against
ischemia compared with those in adult animals, as also
described by Sennlaub et al.51 Administration of AMA0428
diminished the thinning of INL and IPL in the OIR model by
reducing the number of apoptotic cells in INL, pointing to a
possible neuroprotective feature of ROCK inhibition. Of note,
although anti-VEGF-R2 treatment did not affect retinal mor-
phology in our study, it has been described that the currently
used VEGF inhibitors might cause adverse effects linked to
neuronal regression in many organs, including the eye.13,91–93
Therefore, ROCK inhibition might be a safer alternative therapy
for patients with proliferative retinopathies.
Overall, the present data indicate that targeting the Rho/
ROCK pathway with AMA0428 efficiently reduces early DR
changes, such as leukostasis and vessel leakage in the STZ
model, as well as advanced DR features like neovascularization
in the OIR model. Additionally, AMA0428 seems to attenuate
neurodegeneration in both rodent models. These findings make
AMA0428 a promising new candidate with a supplementary
therapeutic benefit in the treatment of proliferative retinopathies.
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